Express Healthcare

BIOTRONIK pacemakers gets CE approval for use in 3 Tesla MRI scans worldwide

89

Reportedly, the only company offering both ICDs and pacemakers approved for 3 T scans

BIOTRONIK has announced CE approval of 3 tesla (T) MRI scanning with exclusion zone for its two latest generations of pacemakers. Reportedly, BIOTRONIK is now the only company offering both implantable cardioverter-defibrillators (ICDs) and pacemakers approved for 3 T scans.

“The benefits of 3 T MRI scanners are clear. 3 T scanners offer superior image quality, as well as a shorter scan time compared to a 1.5 T machine. Patients with ProMRI devices enabling 3 T scans benefit from a shorter time spent in the sometimes uncomfortable MRI machine, while doctors benefit from clearer images to diagnose conditions. Reduced scan times can improve clinical workflow, granting more patients access to this vital diagnostic tool,” commented Dr Maurizio Lunati, Niguarda Hospital, Milan, Italy.

To help physicians keep track of which ProMRI devices and leads are approved in their own region, new functions have been added to the ProMRI Systems. ProMRI System Check allows physicians to verify whether a patient’s individual BIOTRONIK device and lead combination is MR conditional, and under which scanning conditions. It is now available in five languages: English, French, German, Italian and Spanish.

“Along with the development of tools like the ProMRI System Check website, our continued effort to gain MRI approval for all our devices and leads demonstrates BIOTRONIK’s commitment to serving patients and physicians. As 3 T MRI scanners become more and more prevalent, it is essential that device patients are able to access them,” stated Manuel Ortega, Senior VP of BIOTRONIK.

“Through innovation and diligence we have developed the world’s largest portfolio of ProMRI devices. We are pleased to expand our existing portfolio of approved ICDs and pacemakers by gaining CE approval for 3 T MRI scanning for the latest pacemaker generations,” he said.

- Advertisement -

Comments are closed.